What is the Return on Assets (ROA) of Vaccinex this year?
The Return on Assets (ROA) of Vaccinex is -5.58 undefined this year.
Vaccinex ROA 2024
Vaccinex ROA
-5.58
Ticker
VCNX
ISIN
US9186401033
WKN
A2N30M
In 2024, Vaccinex's return on assets (ROA) was -5.58, a 124.53% increase from the -2.48 ROA in the previous year.
Vaccinex Aktienanalyse
What does Vaccinex do?
Vaccinex Inc is a biopharmaceutical company based in Rochester, New York, focusing on the development of novel therapies for a variety of diseases. The company was founded in 2001 by Maurice Zylofo and Dr. Steffen Nock, and has since built an impressive track record in drug development. Vaccinex's business model is based on the discovery and development of specific monoclonal antibodies for the treatment of diseases, particularly cancer. The company has developed a proprietary platform technology called ActivMAb®, which quickly and efficiently identifies potential targets and develops specific antibodies to block or modulate these targets. Vaccinex has several business divisions, including cancer therapy, immunology, cardiology, and neurology. Each of these divisions focuses on specific diseases and potential applications of Vaccinex's technology. The company also has partnerships with other industry leaders, such as Bristol-Myers Squibb and Catalent, to support the development and manufacturing of new drugs. The company has conducted several clinical trials to evaluate the efficacy and safety of its products. Vaccinex's most promising products are VX15/2503, a monoclonal antibody targeting cancer, and PEPCON, a potential vaccine for Alzheimer's disease. VX15/2503 is an antibody that targets the semaphorin 4-D receptor, a molecule that plays a key role in cancer development. The drug has shown in preclinical studies that it can inhibit tumor growth and has shown promise in clinical trials for the treatment of lung cancer and an aggressive brain tumor called glioblastoma. PEPCON is a novel vaccine targeting Alzheimer's disease. The vaccine aims to eliminate the beta-amyloid peptide, which is deposited in the brains of patients with Alzheimer's disease. The drug has shown in early clinical studies that it is able to reduce these brain deposits, which may lead to improved cognitive function. Overall, Vaccinex Inc has a promising future and is well-positioned to develop new and innovative therapies for the treatment of diseases. The company has an impressive track record in drug development and partnering with other industry leaders to support the manufacturing and commercialization of new drugs. With a strong pipeline of promising drug candidates, Vaccinex Inc will continue to play an important role in the development of new treatments. Vaccinex ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Vaccinex's Return on Assets (ROA)
Vaccinex's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Vaccinex's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Vaccinex's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Vaccinex’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Vaccinex stock
What was the ROA of Vaccinex compared to the previous year?
The ROA of Vaccinex has increased by 124.53% compared to the previous year.
What consequences do high ROA have for investors of Vaccinex?
A high ROA is advantageous for investors of Vaccinex, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Vaccinex?
A low ROA can be unfavorable for investors of Vaccinex as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Vaccinex affect the company?
An increase in ROA of Vaccinex can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Vaccinex impact the company?
A reduction in the ROA of Vaccinex can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Vaccinex?
Some factors that can influence the ROA of Vaccinex include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Vaccinex important for investors?
The ROA of Vaccinex is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Vaccinex take to improve ROA?
To improve ROA, Vaccinex can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Vaccinex pay?
Over the past 12 months, Vaccinex paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vaccinex is expected to pay a dividend of 0 USD.
What is the dividend yield of Vaccinex?
The current dividend yield of Vaccinex is .
When does Vaccinex pay dividends?
Vaccinex pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Vaccinex?
Vaccinex paid dividends every year for the past 0 years.
What is the dividend of Vaccinex?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Vaccinex located?
Vaccinex is assigned to the 'Health' sector.
Wann musste ich die Aktien von Vaccinex kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Vaccinex from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.
When did Vaccinex pay the last dividend?
The last dividend was paid out on 10/2/2024.
What was the dividend of Vaccinex in the year 2023?
In the year 2023, Vaccinex distributed 0 USD as dividends.
In which currency does Vaccinex pay out the dividend?
The dividends of Vaccinex are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Vaccinex
Our stock analysis for Vaccinex Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vaccinex Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
